Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol

被引：0
|
作者：
Ditte Hansen
Lisbet Brandi
Knud Rasmussen
机构：
[1] Roskilde Hospital,Medical Department
[2] University of Copenhagen,Department of Surgery and Internal Medicine
来源：
BMC Nephrology | / 10卷
关键词：
Chronic Kidney Disease; Hypercalcemia; Vascular Calcification; Secondary Hyperparathyroidism; Alfacalcidol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] The Clinical Effect of Paricalcitol Treatment on Hemodialysis Patients with Secondary Hyperparathyroidism and the Influence of Abdominal Aortic Calcification
    Liu, Yin
    Yang, Tao
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 221 - 222
  • [22] COMPARISON OF PARATHYROIDECTOMIES WITH PARICALCITOL OR CINACALCET FOR TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN HEMODIALYSIS PATIENTS
    Walton, Surrey M.
    Schumock, Glen T.
    Lee, Todd A.
    Marx, Steven E.
    Audhya, Paul
    Andress, Dennis L.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) : A78 - A78
  • [23] Pulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial
    Sawalmeh, Osama
    Moala, Shaheed
    Hamdan, Zakaria
    Masri, Huda
    Ayoub, Khubaib
    Khazneh, Emad
    Shraim, Mujahed
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2018, 11 : 25 - 32
  • [24] Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
    Rabinovich, MB
    Walton, T
    PHARMACOTHERAPY, 2005, 25 (10): : 1465 - 1465
  • [25] Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis
    Ross, Edward A.
    Tian, Jin
    Abboud, Hanna
    Hippensteel, Richard
    Melnick, Joel Z.
    Pradhan, Rajendra S.
    Williams, Laura A.
    Hamm, L. Lee
    Sprague, Stuart M.
    AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (01) : 97 - 106
  • [26] Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient
    Cozzolino, Mario
    Galassi, Andrea
    Gallieni, Maurizio
    Brancaccio, Diego
    CLINICAL KIDNEY JOURNAL, 2008, 1 (03): : 148 - 150
  • [27] COST-EFFECTIVENESS OF PARICALCITOL VERSUS CALCITRIOL FOR MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN MAINTAIN HAEMODIALYSIS PATIENTS IN BEIJING
    Zhou, Jiannan
    Chen, Gang
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I580 - I581
  • [28] Paricalcitol in the treatment of MHD with secondary hyperparathyroidism and bone pain
    Jingyi Chen
    Liang Cai
    Xiangqiong Wen
    Xin Xie
    Santao Ou
    International Urology and Nephrology, 2023, 55 : 1385 - 1388
  • [29] A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism
    Helen Eddington
    Rajkumar Chinnadurai
    Helen Alderson
    Sara T. Ibrahim
    Constantina Chrysochou
    Darren Green
    Ibi Erekosima
    Alastair Hutchison
    Abdalla Bubtana
    Janet Hegarty
    Philip A. Kalra
    BMC Nephrology, 22
  • [30] A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism
    Eddington, Helen
    Chinnadurai, Rajkumar
    Alderson, Helen
    Ibrahim, Sara T.
    Chrysochou, Constantina
    Green, Darren
    Erekosima, Ibi
    Hutchison, Alastair
    Bubtana, Abdalla
    Hegarty, Janet
    Kalra, Philip A.
    BMC NEPHROLOGY, 2021, 22 (01)
12345